16 innovations from Bar-Ilan University, available for licensing, co-investment, or spin-out through BIRAD.
Shai Rahimipour
There is still an urgent need for effective and accessible treatments for Alzheimer’s disease (AD). Soluble Aβ oligomers have been identified as the most neurotoxic species in AD and tested as potential targets for antibody-based drug development to prevent cognitive decline in patients. However, controversy exists concerning their efficacy and safety. We propose an alternative approach to inhibit the formation of the most neurotoxic Aβ oligomers through the targeted oxidation of specific amino acids to prevent the aggregation and toxicity of Aβ. The selective oxidation is obtained by exploiting reactive singlet oxygen locally produced by the interaction of biocompatible and blood brain barrier permeable multicomponent nanoscintillators with X-rays. We demonstrate that surface-modified nanoscintillators interact selectively with Aβ and upon irradiation with X-ray inhibit the formation of neurotoxic Aβ aggregates both in vitro and in vivo. Feeding transgenic Caenorhabditis elegans expressing human Aβ with the surface-modified nanoscintillators and soft X-ray irradiation reduced Aβ oligomer levels, prolonged lifespan and recovered memory and behavioral deficits, thus warrant further development of X-ray based therapy of AD to reach the clinical trial stage.
Yadid Gal Moshe
New psychodelic - like substance for novel treatment for addiction
Yadid Gal Moshe
Synthetic delta receptor peptide agonists as a new treatment for cocaine addiction and pain.
Yadid Gal Moshe
Mesenchemal stem cell as a new treatment for cocaine addiction.
